Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Advancements in artificial intelligence for prostate cancer: Optimizing diagnosis, treatment, and prognostic assessment
18
Zitationen
14
Autoren
2025
Jahr
Abstract
Objective: This review provides a comprehensive overview of the current research landscape on artificial intelligence (AI) in prostate cancer (PCa) management, highlighting its potential to enhance diagnosis, improve medical image quality, facilitate risk stratification, and aid prognosis. The review also identifies opportunities and challenges associated with integrating AI into clinical practice. Methods: This review synthesizes findings from recent studies on AI applications in PCa management. It examines the use of machine learning and deep learning techniques in diagnostic imaging, surgical skill assessment, and outcome prediction. The analysis emphasizes empirical evidence demonstrating the efficacy and limitations of AI models in clinical settings. Results: AI, particularly machine learning and deep learning algorithms, is improving diagnostic accuracy by analyzing medical images with greater efficiency and precision compared to traditional methods. AI-based tools are also being developed for surgical skill assessment, offering objective evaluations and feedback to surgeons. Additionally, AI applications in predicting patient outcomes are facilitating the creation of personalized treatment plans. Empirical evidence shows that AI models exhibit higher sensitivity and specificity in detecting clinically significant PCa, outperforming conventional diagnostic techniques. Conclusion: AI holds significant promise for transforming PCa management by improving diagnostic accuracy, personalizing treatment plans, and enhancing patient outcomes. While the evidence underscores its potential, challenges such as the need for larger, more diverse datasets and addressing implementation barriers remain critical. Despite these hurdles, the benefits of AI in PCa management represent a compelling area for future research and clinical integration.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.710 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.464 Zit.
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 · 5.215 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.552 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.499 Zit.